SYNERGISTIC EFFECT OF CURCUMIN AND ATIPRIMOD AS POTENT INHIBITORS OF STAT3 AND IL-6 RECEPTOR IN CHORDOMA CELLS

Authors : Esra Aydemir

Pages : 96-102

Doi:10.22531/muglajsci.1438575

View : 26 | Download : 35

Publication Date : 2024-06-30

Article Type : Research

Abstract :Chordoma, is a rare bone tumor, which is characterized by a high recurrence rate and drug resistance in addition to its potential for local invasion, and metastasis. It is a low-grade axial skeletal carcinoma derived from notochord remnants. Molecular pathways that underlie the mechanisms of chordoma pathogenesis are partially elucidated, however, the rate of success in treatment remains to be solved. Constitutively active STAT3 and partially active STAT5 suppress anti-tumor immunity, resulting in increased proliferation, survival and aggressiveness of tumor cells. Persistent activation of STAT3 mediates tumor-promoting inflammation. STAT3 upregulates pro-oncogenic inflammatory pathways, including nuclear factor-κB (NFκB), interleukin-6 (IL-6), and Janus kinase (JAK) pathways. In conclusion, IL6R and STAT3 are promising targets for rerouting inflammation for cancer therapy. In this study, curcumin and atiprimod agents were applied to chordoma cell lines in combination based on molecular docking analyses. The binding efficacy was found favorable for the treatment with two agents and synergistic anti-cancer effects of this combined application were detected on chordoma cells. Molecular docking analyses together with the in vitro results support the idea that application of IL-6R and Stat3 co-inhibition have lethal effects on chordoma cells.
Keywords : IL-6R, Atiprimod, Kurkumin, Moleküler Yerleştirme, Kordoma